Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Depreciation & Amortization (CF) (2022 - 2025)

Historic Depreciation & Amortization (CF) for Entrada Therapeutics (TRDA) over the last 4 years, with Q3 2025 value amounting to $1.2 million.

  • Entrada Therapeutics' Depreciation & Amortization (CF) rose 3333.33% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.2 million, marking a year-over-year increase of 2236.31%. This contributed to the annual value of $3.8 million for FY2024, which is 3375.57% up from last year.
  • Per Entrada Therapeutics' latest filing, its Depreciation & Amortization (CF) stood at $1.2 million for Q3 2025, which was up 3333.33% from $1.1 million recorded in Q2 2025.
  • Entrada Therapeutics' 5-year Depreciation & Amortization (CF) high stood at $1.2 million for Q3 2025, and its period low was $400000.0 during Q1 2022.
  • Its 4-year average for Depreciation & Amortization (CF) is $777133.3, with a median of $800000.0 in 2023.
  • In the last 5 years, Entrada Therapeutics' Depreciation & Amortization (CF) soared by 7264.33% in 2024 and then soared by 128.48% in 2025.
  • Over the past 4 years, Entrada Therapeutics' Depreciation & Amortization (CF) (Quarter) stood at $500000.0 in 2022, then soared by 47.2% to $736000.0 in 2023, then surged by 35.87% to $1.0 million in 2024, then rose by 20.0% to $1.2 million in 2025.
  • Its last three reported values are $1.2 million in Q3 2025, $1.1 million for Q2 2025, and $946000.0 during Q1 2025.